The 'MHC-I (major histocompatibility complex class I)-opathy'concept describes a family of
inflammatory conditions with overlap** clinical manifestations and a strong genetic link to …

In antigen‐presenting cells (APCs), loading of major histocompatibility complex class II
(MHC II) molecules with peptides is regulated by invariant chain (Ii), which blocks MHC II …

Introduction In spontaneous type 1 diabetes (T1D) non-obese diabetic (NOD) mice, the
insulin B chain peptide 9-23 (B: 9-23) can bind to the MHC class II molecule (IAg7) in …

A primary initiating epitope in the NOD mouse model of Type 1 Diabetes (T1D) lies between
residues 9 and 23 of the insulin B chain. The B: 9-23 peptide can bind to the NOD MHC …

A peptide derived from the insulin B chain contains a major epitope for diabetogenic CD4+ T
cells in the NOD mouse model of type 1 diabetes (T1D). This peptide can fill the binding …

In nonobese diabetic (NOD) mice, two sets of autoreactive CD4+ T cells recognize the B: 9–
23 segment of the insulin B chain. One set, type A, recognizes insulin presented by antigen …

Purpose: Cancer vaccines aim to generate and maintain antitumor immune responses. We
designed a phase I/IIa clinical trial to test a vaccine formulation composed of Montanide ISA …

The interaction of antigen-presenting cells with free peptides or a denatured protein can give
rise to peptide–MHC class II complexes that are distinct from those generated after the …

Dedicated to the memory of Professors Henry G. Kunkel and Bruce Merrifield (Rockefeller
University, New York), who introduced us to the fascinating worlds of immunology and …

Chimeric antigen receptor (CAR) T‐cell therapy is an immunotherapy approach that has
played a tremendous role in the battle against cancer for years. Since the CAR T …